Trials / Completed
CompletedNCT03398668
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Neurolief Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Relievion device- Treatment stimulation | 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation |
| DEVICE | Relievion Device- Sham stimulation | 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation |
Timeline
- Start date
- 2018-02-22
- Primary completion
- 2018-12-30
- Completion
- 2018-12-30
- First posted
- 2018-01-12
- Last updated
- 2019-03-13
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03398668. Inclusion in this directory is not an endorsement.